Home > Haematology > EHA 2020 > Plasma Cell Dyscrasias > Daratumumab for light-chain amyloidosis

Daratumumab for light-chain amyloidosis

Presented By
Dr Efstathios Kastritis, National and Kapodistrian University of Athens, Greece
EHA 2020
The ANDROMEDA study demonstrated clear clinical benefit when adding subcutaneous (SC) daratumumab to a combination with cyclophosphamide, bortezomib and dexamethasone (CyBorD) for patients with newly diagnosed light-chain (AL) amyloidosis. Chemotherapy-based combinations are commonly used in AL amyloidosis, but more effective treatments are needed. Dr Efstathios Kastritis (National and Kapodistrian University of Athens, Greece) presented the phase 3 ANDROMEDA study, which evaluated subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) compared with CyBorD alone in newly diagnosed patients with AL amyloidosis [1]. In total, 388 patients with newly diagnosed AL amyloidosis were randomised to receive treatment with either CyBorD alone (n=193) or with the addition of SC daratumumab (n=195; 1,800 mg Q4W). The...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on